The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease
Abstract
Alzheimer's disease is characterized by the deposition of amyloid-β peptide in the brain. N-terminal truncation resulting in the formation of AβN3pE and phosphorylation at serine 8 have been reported to modify aggregation properties of amyloid-β. Biochemically, soluble, dispersible, membrane-associated, and insoluble, plaque-associated amyloid-β aggregates have been distinguished. Soluble and dispersible amyloid-β aggregates are both in mixture with the extracellular or intracellular fluid but dispersible aggregates can be cleared from proteins in solution by ultracentrifugation. To clarify the role of phosphorylated amyloid-β and AβN3pE in soluble, dispersible, membrane-associated, and plaque-associated amyloid-β aggregates in the pathogenesis of Alzheimer's disease we studied brains from 21 cases with symptomatic Alzheimer's disease, 33 pathologically preclinical Alzheimer's disease cases, and 20 control cases. Western blot analysis showed that soluble, dispersible, membrane-associated and plaque-associated amyloid-β aggregates in the earliest preclinical stage of Alzheimer's disease did not exhibit detectable amounts of AβN3pE and phosphorylated amyloid-β. This stage was referred to as biochemical stage 1 of amyloid-β aggregation and accumulation. In biochemical amyloid-β stage 2, AβN3pE was additionally found whereas phosphorylated amyloid-β was restricted to biochemical amyloid-β stage 3, the last stage of amyloid-β aggregation. Phosphorylated amyloid-β was seen in the dispersible, membrane-associated, and plaque-associated fraction. All cases with symptomatic Alzheimer's disease in our sample fulfilled biochemical amyloid-β stage 3 criteria, i.e. detection of phosphorylated amyloid-β. Most, but not all, cases with pathologically preclinical Alzheimer's disease had biochemical amyloid-β stages 1 or 2. Immunohistochemistry confirmed the hierarchical occurrence of amyloid-β, AβN3pE, and phosphorylated amyloid-β in amyloid plaques. Phosphorylated amyloid-β containing plaques were, thereby, seen in all symptomatic cases with Alzheimer's disease but only in a few non-demented control subjects. The biochemical amyloid-β stages correlated with the expansion of amyloid-β plaque deposition and with that of neurofibrillary tangle pathology. Taken together, we demonstrate that AβN3pE and phosphorylated amyloid-β are not only detectable in plaques, but also in soluble and dispersible amyloid-β aggregates outside of plaques. They occur in a hierarchical sequence that allows the distinction of three stages. In light of our findings, it is tempting to speculate that this hierarchical, biochemical sequence of amyloid-β aggregation and accumulation is related to disease progression and may be relevant for an increasing toxicity of amyloid-β aggregates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…protofibrils and fibrils, membrane-associated (SDS soluble) Ab aggregates, and solid, plaque-associated (formic acid soluble) Ab fibrils (Harper et al., 1997; Walsh et al., 1997; Kayed et al., 2003; Lesne et al., 2006; Habicht et al., 2007; Shankar et al., 2008; Rijal Upadhaya et al., 2012a).”
RetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 3×
“…protofibrils and fibrils, membrane-associated (SDS soluble) Ab aggregates, and solid, plaque-associated (formic acid soluble) Ab fibrils (Harper et al., 1997; Walsh et al., 1997; Kayed et al., 2003; Lesne et al., 2006; Habicht et al., 2007; Shankar et al., 2008; Rijal Upadhaya et al., 2012a).”
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Self-citationBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Research works printed but not linked: 20
- Alzheimer, 1907, Ueber eine eigenartige Erkrankung der Hirnrinde, Allg Zschr Psych, 64, 146
- Andorfer, 2000, PKA phosphorylations on tau: developmental studies in the mouse, Dev Neurosci, 22, 303, 10.1159/000017454 · DOI
- Arriagada, 1992, Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease, Neurology, 42, 1681, 10.1212/WNL.42.9.1681 · DOI · Paper page
- Dickson, 2011, Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau), J Mol Neurosci, 45, 384, 10.1007/s12031-011-9589-0 · DOI · Paper page
- Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, 734, 10.1016/S1474-4422(07)70178-3 · DOI · Paper page
- Habicht, 2007, Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils, Proc Natl Acad Sci USA, 104, 19232, 10.1073/pnas.0703793104 · DOI · Paper page
- Harper, 1997, Observation of metastable Abeta amyloid protofibrils by atomic force microscopy, Chem Biol, 4, 119, 10.1016/S1074-5521(97)90255-6 · DOI · Paper page
- Iwatsubo, 1996, Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques, Am J Pathol, 149, 1823
- Kim, 1988, Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide, Neurosci Res Commun, 2, 121
- Kumar, 2011, Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease, EMBO J, 30, 2255, 10.1038/emboj.2011.138 · DOI · Paper page
- Kumar, 2013, Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease, Acta Neuropathol, 125, 699, 10.1007/s00401-013-1107-8 · DOI
- Masters, 1985, Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels, EMBO J, 4, 2757, 10.1002/j.1460-2075.1985.tb04000.x · DOI · Paper page
- Mc Donald, 2010, The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia, Brain, 133, 1328, 10.1093/brain/awq065 · DOI · Paper page
- Monsell, 2013, Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology, Neurology, 80, 2121, 10.1212/WNL.0b013e318295d7a1 · DOI
- Rijal Upadhaya, 2012, Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice, Neurobiol Aging, 33, 2641, 10.1016/j.neurobiolaging.2011.12.032 · DOI
- Rijal Upadhaya, 2012, High-molecular weight Aβ-oligomers and protofibrils are the predominant Aβ-species in the native soluble protein fraction of the AD brain, J Cell Mol Med, 16, 287, 10.1111/j.1582-4934.2011.01306.x · DOI
- Schlenzig, 2009, Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides, Biochemistry, 48, 7072, 10.1021/bi900818a · DOI · Paper page
- Thal, 2013, Pathology of clinical and preclinical Alzheimer's disease, Eur Arch Psychiatry Clin Neurosci, 263, S137, 10.1007/s00406-013-0449-5 · DOI
- Walsh, 1997, Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate, J Biol Chem, 272, 22364, 10.1074/jbc.272.35.22364 · DOI · Paper page
- Watt, 2013, Oligomers, fact or artefact? SDS-PAGE induces dimerization of beta-amyloid in human brain samples, Acta Neuropathol, 125, 549, 10.1007/s00401-013-1083-z · DOI
Cited by
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467
Self-citationThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
Interactions of pathological proteins in neurodegenerative diseases
Spires-Jones, T. L., Attems, J., & Thal, D. R. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1709-7 · Cited by 429
Self-citationAlzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease
Thal, D. R., Walter, J., Saido, T. C., & Fändrich, M. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1375-y · Cited by 319
Self-citationInterrogating Amyloid Aggregates using Fluorescent Probes
Aliyan, A., Cook, N. P., & Martí, A. A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00404 · Cited by 290
Walgrave, H., Balusu, S., Snoeck, S., Vanden Eynden, E., Craessaerts, K., Thrupp, N., Wolfs, L., Horré, K., Fourne, Y., Ronisz, A., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.05.001 · Cited by 175
Self-citationPART, a distinct tauopathy, different from classical sporadic Alzheimer disease.
Jellinger, K. A., Alafuzoff, I., Attems, J., Beach, T. G., Cairns, N. J., Crary, J. F., Dickson, D. W., Hof, P. R., Hyman, B. T., Jack, C. R., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1407-2 · Cited by 171
Self-citationThal, D. R., Beach, T. G., Zanette, M., Heurling, K., Chakrabarty, A., Ismail, A., Smith, A. P. L., & Buckley, C. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.018 · Cited by 159
Self-citationThe amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome
Drummond, E., Kavanagh, T., Pires, G., Marta-Ariza, M., Kanshin, E., Nayak, S., Faustin, A., Berdah, V., Ueberheide, B., & Wisniewski, T. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01356-1 · Cited by 137
Gomes, L. A., Hipp, S. A., Rijal Upadhaya, A., Balakrishnan, K., Ospitalieri, S., Koper, M. J., Largo-Barrientos, P., Uytterhoeven, V., Reichwald, J., Rabe, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02053-5 · Cited by 125
Self-citationThal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
Uhlmann, R. E., Rother, C., Rasmussen, J., Schelle, J., Bergmann, C., Ullrich Gavilanes, E. M., Fritschi, S. K., Buehler, A., Baumann, F., Skodras, A., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00737-w · Cited by 87
Chakrabarti, M., McDonald, A. J., Will Reed, J., Moss, M. A., Das, B. C., & Ray, S. K. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150450 · Cited by 57
Takeda, K., Uda, A., Mitsubori, M., Nagashima, S., Iwasaki, H., Ito, N., Shiiba, I., Ishido, S., Matsuoka, M., Inatome, R., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01720-2 · Cited by 32
Experimental evidence for temporal uncoupling of brain Aβ deposition and neurodegenerative sequelae
Rother, C., Uhlmann, R. E., Müller, S. A., Schelle, J., Skodras, A., Obermüller, U., Häsler, L. M., Lambert, M., Baumann, F., Xu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34538-5 · Cited by 28
Biomarker-based signature of alzheimer's disease in pre-MCI individuals
Chipi, E., Salvadori, N., Farotti, L., & Parnetti, L. (2019) · Brain Sciences · doi:10.3390/brainsci9090213 · Cited by 27
Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease
Li, X., Tsolis, K. C., Koper, M. J., Ronisz, A., Ospitalieri, S., von Arnim, C. A. F., Vandenberghe, R., Tousseyn, T., Scheuerle, A., Economou, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12345 · Cited by 27
Self-citationSchlenzig, D., Cynis, H., Hartlage-Rübsamen, M., Zeitschel, U., Menge, K., Fothe, A., Ramsbeck, D., Spahn, C., Wermann, M., Roßner, S., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171183 · Cited by 27
Metadata
- Authors
- Rijal Upadhaya, A., Kosterin, I., Kumar, S., von Arnim, C. A. F., Yamaguchi, H., Fändrich, M., Walter, J., & Thal, D. R.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02-10
- Volume
- 137
- Issue
- 3
- Pages
- 887-903
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2154735761
- Cited by
- 166
- References
- 23
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.